NexGenix, Universite Louis Pasteur, Centre National de la Recherche Scientifique deal

NexGenix received exclusive, worldwide rights to develop and commercialize the university and center's preclinical Hsp90 inhibitors as therapeutics and diagnostics. The company initially will focus o...